Pertuzumab (Perjeta)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Humanized monoclonal antibody that binds to the extracellular dimerization subdomain II of HER2, preventing dimerization with other HER receptors (i.e. EGFR/HER1, HER3, and HER4). Pertuzumab inhibits ligand-initiated intracellular signaling via the MAP (mitogen-activated protein) kinase and PI3K (phosphoinositide 3-kinase) pathways, which results in cell growth arrest and apoptosis. Also stimulates antibody-dependent cell-mediated cytotoxicity (ADCC).[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: 2C4, Rhumab 2C4.
  • Brand names: Omnitarg, Perjeta

References

  1. 1.0 1.1 1.2 Pertuzumab (Perjeta) package insert
  2. Pertuzumab (Perjeta) package insert (locally hosted backup)
  3. Perjeta manufacturer's website
  4. Pertuzumab (Perjeta) patient drug information (Chemocare)
  5. Pertuzumab (Perjeta) patient drug information
  6. Pertuzumab (Perjeta) patient drug information (UpToDate)